A drug approved for pancreatic cancer just a week ago is already showing signs it could help treat lung cancer, the world's leading cause of cancer death.
Early trial results published in the New England Journal of Medicine found that tumours shrank in more than 30 per cent of lung cancer patients given the drug, called daraxonrasib (brand name Rasonque).